FDA approves St. Jude Medical’s SyncAV CRT software

St. Jude Medical (NYSE:STJ) said today that the FDA approve its SyncAV cardiac resynchronization therapy software, which is designed to automatically adjust pacing based on real-time changes in a patient’s cardiac condition. The new software is designed to work with or independently of St. Jude’s multi-point pacing technology, which allows physicians to tailor pacing therapy by controlling multiple pulses to the left ventricle for each heartbeat. “St. Jude Medical has a proven dedication to continued leadership in heart failure management to help physicians manage some of their most complex patients. Approval of the SyncAV CRT technology is important for those patients who are not getting the desired response from traditional cardiac resynchronization therapy,” chief medical officer Dr. Mark Carlson said in prepared remarks. “The SyncAV software used alone or with MultiPoint Pacing technology offers the enhanced potential to optimize heart failure therapy for patients who previously did not respond to traditional CRT therapy,” added Dr. Adam Shapira of Baylor University’s Heart Hospital in Plano, Texas. “The SyncAV software also offers the ability for automated setup, which facilitates efficient programming both remotely via Merlin and directly in the office.” The post FDA approves St. Jude Medical’s SyncAV CRT software appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Cardiac Rhythm Management St. Jude Medical Source Type: news